C4 Therapeutics (CCCC) Cash & Current Investments (2019 - 2026)

C4 Therapeutics' Cash & Current Investments history runs 8 years deep, the most recent figure standing at $235.7 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 9.57% year-over-year to $235.7 million; the TTM figure through Mar 2026 stood at $235.7 million (up 9.57% YoY), while the FY2025 annual figure was $248.5 million, up 1.48% from the prior year.
• Cash & Current Investments was $235.7 million for Q1 2026 at C4 Therapeutics, down from $248.5 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $313.7 million in Q3 2022 to a low of $191.9 million in Q3 2025.
• Historically, Cash & Current Investments has averaged $254.4 million across 5 years, with a median of $255.6 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Cash & Current Investments sank 33.94% in 2022, then grew 18.04% in 2024.
• A 5-year view of Cash & Current Investments shows it stood at $276.2 million in 2022, then slipped by 8.14% to $253.7 million in 2023, then slipped by 3.46% to $244.9 million in 2024, then climbed by 1.48% to $248.5 million in 2025, then decreased by 5.18% to $235.7 million in 2026.
• The last three Cash & Current Investments figures came in at $235.7 million (Q1 2026), $248.5 million (Q4 2025), and $191.9 million (Q3 2025), per Business Quant data.